Parke-Davis

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
ERNA, Bates College, Organic chemistry, Drug discovery, Publication, Schering-Plough, Research, University, Drug development, Retirement, Abstract, Messenger, Senior advisor, Bristol, Patient, Doctor of Philosophy, United States Air Force Scientific Advisory Board, Parke-Davis, Pharmaceutical industry, Eterna, Pfizer, Chemistry

Bristol is a seasoned biopharmaceutical executive who has excelled as a corporate partner, board member, and strategic and technical advisor within our industry,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna.

Key Points: 
  • Bristol is a seasoned biopharmaceutical executive who has excelled as a corporate partner, board member, and strategic and technical advisor within our industry,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna.
  • Before that, he worked at Parke-Davis for 20 years, where he held positions of increasing responsibility in Chemistry and Drug Discovery and participated in collaboration oversight committees.
  • Early in his career, Dr. Bristol was a Principal Scientist at Schering-Plough, leading the gastrointestinal research program.
  • His drug discovery research has resulted in numerous publications, abstracts, and patents.

Metrion Biosciences Expands Senior Leadership Team With Appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO

Retrieved on: 
Thursday, July 6, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Innovate UK, University, Drug discovery, NeuroSolutions, Sheffield Hallam University, Doctor of Philosophy, Innovation, Parke-Davis, BK, Imperial College London, Safety, Pharmaceutical industry, Electrophysiology

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.

Key Points: 
  • Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.
  • This expansion of the senior leadership team will enable Metrion to continue to evolve its ion channel drug discovery service capabilities and ensure the Company delivers ion channel drug discovery services of the highest quality to its customers.
  • Edward obtained his PhD from Imperial College London and completed postdoctoral studies at the University of Cambridge and Parke-Davis UK.
  • Dr Andy Southan, Chief Executive, Metrion Biosciences, said: “I am very pleased to announce these senior management appointments.

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

Retrieved on: 
Wednesday, November 30, 2022
Marketing, COVID-19, Exchange, PLE, Parke-Davis, Sarcoma, Peptide, University, Acceleration, TG, Risk, Novartis, PDC, Therapy, Employment, Safety, Sanofi, Patient, Follicular lymphoma, ImClone Systems, Regulation, Common stock, Neuroblastoma, Drug discovery, Hematology, Security (finance), Lymphoma, News, Cancer, Business administration, Bachelor of Business Administration, Research, Abraxis BioScience, Christian democracy, Brain, FDA, WM, Pharmaceutical industry, Management, Lenalidomide

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022.
  • Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology.
  • As we prepare for the approval of iopofosine, his professional background is ideally suited for our newly created position of chief commercial officer and we look forward to his leadership, said James Caruso, president and chief executive officer of Cellectar.
  • Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.

Swapna Allapur Joins Everest Group as Chief People Officer

Retrieved on: 
Wednesday, April 6, 2022
Tata Institute of Social Sciences, Parke-Davis, Mahindra Satyam, Growth, Social science, Research, Certification, Carnegie Mellon University, CEO, Bloomberg Businessweek, Workforce, Sun Life Financial, Technology, Acquisition, Human, HMT, Deloitte, Marketing, Management, DALLAS, Mass concentration (astronomy)

DALLAS, April 6, 2022 /PRNewswire-PRWeb/ --Swapna Allapur has joined Everest Group—a global research firm focused on strategic IT, business services, engineering services and sourcing—as chief people officer. Allapur, based in Bengaluru, India, is responsible for the human resources strategy and operations for the firm, which employs nearly 400 people across the U.S., Canada, Europe, India and Latin America.

Key Points: 
  • DALLAS, April 6, 2022 /PRNewswire-PRWeb/ --Swapna Allapur has joined Everest Groupa global research firm focused on strategic IT, business services, engineering services and sourcingas chief people officer.
  • A global HR professional with more than 25 years of multinational experience, Allapur will direct all aspects of the Everest Group people strategy and function, including acquiring, nurturing and retaining talent.
  • "Everest Group is well respected by its Global 1000 client list for its depth of expertise," said Allapur.
  • Prior to joining Everest Group, Allapur was with Deloitte Consulting for a decade in multiple senior roles.

Scipher Medicine Appoints Richard Blackburn to its Advisory Board

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Sterling Drug, LinkedIn, Solution, Immunology, Physician, Sickle Cell Anemia, a Molecular Disease, Degenerative disease, Medicine, Time, Inflammation, Patient, Therapy, Parke-Davis, Janssen Pharmaceuticals, Multimedia, Twitter, Precision medicine, Pharmaceutical industry, Management, Pfizer, Facebook

Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the appointment of Richard Blackburn to its advisory board.

Key Points: 
  • Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the appointment of Richard Blackburn to its advisory board.
  • View the full release here: https://www.businesswire.com/news/home/20211216006082/en/
    Richard Blackburn joins Scipher Medicine advisory board.
  • Scipher Medicine is bringing forward innovative precision medicine solutions that benefit patients, physicians, and the healthcare system.
  • We are pleased to welcome Richard to the team, said Alif Saleh, chief executive officer of Scipher Medicine.

Mission BioCapital Announces $275 Million Fund V

Retrieved on: 
Thursday, November 4, 2021
Science, Other Science, Biotechnology, Health, Consulting, Medical Devices, Professional Services, Clinical Trials, Science, Technology, Creative Biolabs, Warner–Lambert, Drug development, Biomedical Research, Pfizer, NASDAQ, FDA, Novartis Institute for Tropical Diseases, LabCentral, Rachel Haurwitz, LLC, Investment, Parke-Davis, Therapy, Mission, Telo, MBC, Pharmaceutical industry, Management

Mission BioCapital V LP is more than double the size of the firms prior fund.

Key Points: 
  • Mission BioCapital V LP is more than double the size of the firms prior fund.
  • Our team empowers exceptional biotech entrepreneurs from all walks of life, said Peter D. Parker, co-founder and managing general partner of Mission BioCapital.
  • Mission BioCapital has already funded seven companies from the new fund, including four where it has played a co-founder role ARase Therapeutics, Arclight Therapeutics LLC, Jupiter Bioventures, and Telo Therapeutics.
  • Prior to joining Mission BioCapital, Dr. Tregay served as founder, president and chief executive officer of FORMA Therapeutics (NASDAQ: FMTX), raising $875 million in non-dilutive funding alongside venture investments of $44 million and advancing seven clinical drug candidates.

Phosplatin Therapeutics Appoints Industry Veteran Elizabeth Tallett to Board of Directors

Retrieved on: 
Wednesday, September 29, 2021
Anthem Inc. (album), Merck Serono, Therapy, Meredith, Board of directors, Immunogenic cell death, Cancer, Patient, Board, Toxicity, Parke-Davis, CEO, Industry, Merck Group, Family, Trial of the century, Drug resistance, Research, Drug development, Meredith Corporation, Management, Pharmaceutical industry

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Phosplatin Therapeutics Inc. , a clinical stage pharmaceutical company focused on oncology therapeutics, todayannounced the appointment of Elizabeth Tallett to the company's Board of Directors.

Key Points: 
  • NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Phosplatin Therapeutics Inc. , a clinical stage pharmaceutical company focused on oncology therapeutics, todayannounced the appointment of Elizabeth Tallett to the company's Board of Directors.
  • Ms. Tallett brings a wealth of industry experience to Phosplatin, and the company will benefit from her extensive drug development and commercial insights as it advances its lead therapeutic candidate, PT-112.
  • Ms. Tallett has more than 35 years of experience across strategic leadership and operational roles in worldwide biopharmaceutical companies.
  • She was Principal of Hunter Partners, which advised Phosplatin Therapeutics early in its development.

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib

Retrieved on: 
Monday, June 28, 2021
Pfizer, Chemical compounds, Health sciences, Health care, Lasofoxifene, Phenols, Pyrrolidines, Warner–Lambert, Pharmaceutical industry in China, Parke-Davis, Pharmaceutical industry

Sermonix expects initial data from the trial to be available in the first half of 2022.

Key Points: 
  • Sermonix expects initial data from the trial to be available in the first half of 2022.
  • We are delighted to have promptly completed enrollment and thank our participants, their families and clinical centers for supporting our efforts.
  • It is Sermonixs second Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) study and is known as ELAINE 2.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lamberts Pharmaceutical Division.

Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer

Retrieved on: 
Wednesday, April 21, 2021
Pfizer, Chemical compounds, Organic compounds, Lasofoxifene, Phenols, Pyrrolidines, University of Utah, Gertz, Huntsman, Warner–Lambert, Parke-Davis

\xe2\x80\x9cThe unique ESR1 model system is state-of-the-art for this exploration and Dr. Gertz is an esteemed partner with whom it is an honor for Sermonix to collaborate.\xe2\x80\x9d\nDr.

Key Points: 
  • \xe2\x80\x9cThe unique ESR1 model system is state-of-the-art for this exploration and Dr. Gertz is an esteemed partner with whom it is an honor for Sermonix to collaborate.\xe2\x80\x9d\nDr.
  • Gertz is a cancer researcher at Huntsman Cancer Institute and associate professor of oncological sciences at the University of Utah.
  • Lasofoxifene\xe2\x80\x99s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert\xe2\x80\x99s Pharmaceutical Division.

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

Retrieved on: 
Monday, June 10, 2019
Companies, Pfizer, Health, Articles, Covidien, Mannebach, Vulkaneifel, Mallinckrodt, Mannebach, Warner–Lambert, Regulatory affairs, Parke-Davis, Pharmaceutical industry in China

Dr. Mannebach has more than 30 years of experience in the pharmaceutical industry in leadership roles including Parke-Davis, Warner Lambert, Pharmacia, Baxter, and Pfizer.

Key Points: 
  • Dr. Mannebach has more than 30 years of experience in the pharmaceutical industry in leadership roles including Parke-Davis, Warner Lambert, Pharmacia, Baxter, and Pfizer.
  • Dr. Mannebach spent most of the last decade as Vice President of Global Regulatory Affairs and as a member of the Executive Management Team at Covidien and Mallinckrodt Pharmaceuticals.
  • "Mark's global regulatory expertise and experience will strengthen our leadership team and execution.
  • Previously, Dr. Mannebach was Vice President of U.S. Regulatory Affairs and Quality Assurance at Santen Incorporated.